Navigation Links
Genaera Corporation Announces Third Quarter Financial Results
Date:11/9/2007

tements reflect management's current views and are based on certain expectations and assumptions. Such statements include, among others, statements regarding the preliminary results, clinical development plans and prospects for Genaera's programs including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM), or squalamine. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to: Genaera's history of operating losses since inception and its need for additional funds to operate its business; the costs, delays and uncertainties inherent in scientific research, drug development, clinical trials and the regulatory approval process; the risk that clinical trials for Genaera's product candidates, including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM), or squalamine may be delayed or may not be successful; the risk that Genaera may not obtain regulatory approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and interpreting data, regulatory interpretations of clinical risk and benefit, or otherwise; Genaera's reliance on its collaborators, in connection with the development and commercialization of Genaera's product candidates; market acceptance of Genaera's products, if regulatory approval is achieved; competition; general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industry; and the other risks and uncertainties discussed in this announcement and in Genaera's filings with
'/>"/>
SOURCE Genaera Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Genaera Elects New Board Member and Announces Executive Appointments
2. Genaera to Present at Biotech 2007 and BIO InvestorForum
3. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
4. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
5. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
6. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
7. BioElectronics Corporation Announces Singapore and Malaysia Sales
8. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
9. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
10. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
11. Luminex Corporation to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/2/2015)... Latham, NY (PRWEB) April 02, 2015 ... feature low noise, high sensitivity and high-speed response. Marktech ... in a TO-46 metal can with active areas of ... such as receivers, sensors and high speed fiber modules. ... is 0.9um to 1.7um. These parts offer considerable speed ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 Biosearch ... Biosearch to make, use, market and sell Co-Diagnostics’ ... licenses CoPrimers™ technology to Biosearch for its own ... greatly reduces the occurrence of primer-dimers, without the ... increased sensitivity and lower test prices. , ...
(Date:4/1/2015)...  VLP Therapeutics, LLC. ("VLP"), a Gaithersburg ... development of therapeutic and preventative vaccines and next generation ... technology, today announced that it has entered into a research ... Nagasaki University in Japan ... development of dengue vaccine candidates. "I ...
(Date:4/1/2015)... April 1, 2015  EMD Serono, the U.S. biopharmaceuticals ... , announced today the appointment of Frederick E. ... and Immunology. In this capacity, he will lead the ... projects and collaborations for Rebif ® (interferon beta-1a) ... Dr. Munschauer joins EMD Serono from ...
Breaking Biology Technology:Marktech Optoelectronics Announces High Speed InGaAs PIN Diode 1.7µm 2Biosearch and Co-Diagnostics Sign Cooperative Primers Agreement 2Biosearch and Co-Diagnostics Sign Cooperative Primers Agreement 3VLP Therapeutics Enters Collaboration with Institute of Tropical Medicine, Nagasaki University 2VLP Therapeutics Enters Collaboration with Institute of Tropical Medicine, Nagasaki University 3EMD Serono Appoints Frederick E. Munschauer M.D., FAAN to Vice President of Medical Affairs, Neurology and Immunology 2EMD Serono Appoints Frederick E. Munschauer M.D., FAAN to Vice President of Medical Affairs, Neurology and Immunology 3EMD Serono Appoints Frederick E. Munschauer M.D., FAAN to Vice President of Medical Affairs, Neurology and Immunology 4EMD Serono Appoints Frederick E. Munschauer M.D., FAAN to Vice President of Medical Affairs, Neurology and Immunology 5
... Wis. One of the IT industry news rags was ... major players in radio frequency ID tag manufacture. Almost as ... claiming failure rates of up to 20 percent. , ... quality or even embedded tags being crunched when the paper ...
... will offer the Microsoft Education Services of Madison-based ... Atlanta area, the two companies announced Tuesday. The I.B.I.S., Inc. ... from end user applications to technical courses, including Windows Server, ... in Stevens Point and Saint Clare's Hospital in ...
... - The Douglas Stewart Co., a ... announced a partnership with Mindjet Corp. to ... software applications to more than 4,500 academic resellers and ... , ,The Douglas Stewart Co., based in Madison, ...
Cached Biology Technology:The more things change ... 2The more things change ... 3Tech Digest: Inacom; St. Michael's, St. Clare's hospitals; Merge eMed; Advanced Data-Comm; Blue Cross and Blue Shield 2
(Date:4/2/2015)... Fingerprint Cards (FPC) has received ... the distributor World Peace Industrial Group (WPI), part of ... the major part of the shipments will take place ... smartphone manufacturers in China . The ... communicated revenue guidance of + 1 000 MSEK for 2015.  ...
(Date:3/31/2015)... --  Guidepoint , a leading global research services firm, ... TRACKER, part of the Guidepoint TRACKER suite ... device and therapeutics markets. The Post-Surgical Pain Management TRACKER ... share, and adoption rates across three major modalities used ... The Post-Surgical Pain Management TRACKER will provide length ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and Markets ... "Face and Voice Biometrics - Global Strategic Business Report" report ... for Face and Voice Biometrics in US$ Thousands by the following ... analytics for the US, Canada , ... , Middle East & ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
... Eating a fatty fast food meal is never good ... is even worse, according to a new University of Guelph ... a healthy person,s blood sugar levels spike after eating a ... a fatty meal and caffeinated coffee jumping to levels ...
... the AIDS virus,s protein envelope once considered an improbable target ... most promising, new research by Dana-Farber Cancer Institute scientists indicates. ... the V3 loop, is an attractive vaccine target because immune ... multiple genetic subtypes of HIV-1, the virus that causes AIDS. ...
... "skin" of most every cell in your body, but the ... be rendered by many experimental techniques. A team of scientists ... and University of California, Irvine, recently developed a way to ... role of cholesterol within this boundary between the cell and ...
Cached Biology News:Got a craving for fast food? Skip the coffee, study says 2Study identifies promising target for AIDS vaccine 2Study identifies promising target for AIDS vaccine 3Closer look at cell membrane shows cholesterol 'keeping order' 2
Eliminate electrical interference from any analog signal, without filtering. Ideal for electrophysiology applications like EKG, EMG, and EEGs. Removes 50/60hz noise and harmonics caused by grounding ...
... SizeSep 400 Spun Columns, 10. *SizeSep 400 ... > 400 base pairs in length. ... CL-4B and pre-equilibrated in distilled water containing 0.15% ... than ~ 400 base pairs. *Extremely ...
... GFX Purification Kit, 25 purifications. ... cDNA probesProvides efficient removal of unincorporated ... reactions with superior yields of labeled ... purification of cDNA labeled by either ...
... reagents for the isolation of genomic DNA. ... the isolation of genomic DNA from blood. ... the isolation of genomic DNA from plants. ... be used for restriction endonuclease digestion Southern ...
Biology Products: